The Trump administration on Tuesday announced that it would halt research on the medical use of marijuana, but would still allow it to be used to treat some patients with the drug.

The decision, made at the request of the Drug Enforcement Administration (DEA), comes as a major shift in the nation’s marijuana policy.

The Trump Administration has previously said it supports medical marijuana use and will allow researchers to test it for safety and effectiveness in patients with chronic conditions.

The DEA has also said it is in the process of reviewing applications to conduct clinical trials of medical marijuana and is expected to take a stance on the issue within the next few months.

While some medical researchers are already working to create marijuana strains that will be used for treating pain, the Trump Administration’s move is a major step back from previous drug policy stances, which have been more restrictive.

It is unclear how the DEA’s position will affect the number of medical researchers who can study marijuana strains.

The announcement comes just weeks after the DEA released a list of strains that were currently approved for use in the U.S. and which are currently being studied in the field.

The new guidelines include some strains that have already been approved for clinical trials, but others that are in the pipeline for FDA review.

For example, the UVA-1 strain, which is approved for cancer treatment, has already been tested and approved for several sclerosis, AIDS, and Crohn’s disease.

The list includes the FDA’s most recently approved and approved non-psychoactive cannabinoid strains.

Researchers will still be able to continue testing marijuana strains for potential therapeutic applications and are encouraged to explore potential compounds that might be beneficial for specific diseases.

For instance, researchers are also encouraged to investigate potential anti-inflammatory and anti-epileptic properties in marijuana strains, and the DEA is also encouraging them to further explore possible potential antiaging properties in some marijuana strains and cannabinoids.

While the DEA has not yet announced the number, it is likely that the agency’s new policy will significantly reduce the number and quality of cannabinoid research studies in the future.

This news comes at a time when some states are moving to allow the recreational use of cannabis for medical purposes.

California has legalized recreational use for adults, and a similar bill is now before the state legislature.

The Associated Press contributed to this report.